Ginkgo Bioworks Holdings, Inc.
DNA · XNYSCIK 1830214fmd_1ZPSKKHAZ3F7A33NTFWETK2DNJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 54 | 77 | 314 | 478 | 251 | 227 | 170 |
| Net interest income | (48) | 12 | (10) | – | – | – | – |
| Realized investment gains (losses) | (27) | (4) | (12) | (53) | (55) | (29) | (16) |
| Research and development | 96 | 160 | 1,150 | 1,053 | 581 | 424 | 244 |
| Compensation and benefits | 0 | – | – | – | – | – | – |
| Total operating expenses | 126 | 214 | 2,142 | 2,687 | 1,116 | 787 | 485 |
| Operating income | (72) | (137) | (1,828) | (2,209) | (864) | (560) | (315) |
| Interest expense | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | 12 | (10) | 88 | (29) | 12 | 2 |
| Income before taxes | (120) | (125) | (1,838) | (2,121) | (893) | (548) | (314) |
| Income tax expense | 0 | 2 | (1) | (15) | (0) | (0) | (1) |
| Net income from continuing operations | (120) | (127) | (1,837) | (2,106) | (893) | (547) | (313) |
| Net income | (119) | (127) | (1,830) | (2,105) | (893) | (547) | (313) |